About the Authors

Veera R. Konda

veerakonda@kindextherapeutics.com

Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America

Anuradha Desai

Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America

Gary Darland

Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America

Neile Grayson

Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America

Jeffrey S. Bland

Affiliation KinDex Therapeutics, LLC, Seattle, Washington, United States of America

Competing Interests

The authors have declared that there is no duality of interest associated with this manuscript. The authors have the following interests: All authors of the manuscript work or have worked as employees of or consultants for KinDex Therapeutics, LLC, which funded this study, and this article was created during the course of that work. Phase 1 clinical development of KDT501 has been successfully completed and further clinical development studies of this compound are anticipated. There are no declarations concerning marketed products. KinDex holds the following patent relating to material pertinent to this research: US 8, 410, 178 B2. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. All authors also declare no conflict of interest resulting from financial or non-financial competing interests.

Author Contributions

Conceived and designed the experiments: VK AD GD NG JB. Performed the experiments: AD. Analyzed the data: VK GD. Contributed reagents/materials/analysis tools: AD VK GD NG. Wrote the paper: AD VK GD NG JB.